This is the authors' abstract. We don't add key points for this paper.
Maternal hypertensive treatment with angiotensin receptor blockers (ARBs) during the second and third trimester of pregnancy is associated with several fetal and neonatal complications, and potential adverse outcomes. We report a neonate presenting with transient renal acute failure during the first days of life after maternal treatment with ARBs. Women who became pregnant while taking one of these drugs must modify antihypertensive therapy with a different class drug as soon as pregnancy is recognised.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Marchetto et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: